These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 31814481)
1. Successful cessation of tumor necrosis factor inhibitor treatment in rheumatoid arthritis patients and potential predictors for early flare: An observational study in routine clinical care. Naniwa T; Iwagaitsu S; Kajiura M Mod Rheumatol; 2020 Nov; 30(6):948-958. PubMed ID: 31814481 [No Abstract] [Full Text] [Related]
2. Vasodilator function worsens after cessation of tumour necrosis factor inhibitor therapy in patients with rheumatoid arthritis only if a flare occurs. Rongen GA; van Ingen I; Kok M; Vonkeman H; Janssen M; Jansen TL Clin Rheumatol; 2018 Apr; 37(4):909-916. PubMed ID: 29307093 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of add-on tacrolimus on methotrexate to maintain clinical remission after rediscontinuation of a tumor necrosis factor inhibitor in rheumatoid arthritis patients who relapsed shortly after discontinuation of the same tumor necrosis factor inhibitor due to clinical remission. Naniwa T; Iwagaitsu S; Kajiura M Mod Rheumatol; 2017 Jan; 27(1):29-34. PubMed ID: 27143107 [TBL] [Abstract][Full Text] [Related]
4. Predictors of Treatment Change Among Patients with Rheumatoid Arthritis Treated with TNF Inhibitors as First-Line Biologic Agent in the USA: A Cohort Study from Longitudinal Electronic Health Records. Jin Y; Landon JE; Krueger W; Liede A; Desai RJ; Kim SC BioDrugs; 2022 Jul; 36(4):521-535. PubMed ID: 35771381 [TBL] [Abstract][Full Text] [Related]
5. Association between seropositivity and discontinuation of tumor necrosis factor inhibitors due to ineffectiveness in rheumatoid arthritis. Ogawa Y; Takahashi N; Kaneko A; Hirano Y; Kanayama Y; Yabe Y; Oguchi T; Fujibayashi T; Takagi H; Hanabayashi M; Funahashi K; Hayashi M; Tsuboi S; Asai S; Asai N; Matsumoto T; Sobue Y; Ishiguro N; Kojima T Clin Rheumatol; 2019 Oct; 38(10):2757-2763. PubMed ID: 31179526 [TBL] [Abstract][Full Text] [Related]
6. Sustained remission with methotrexate monotherapy after 22-week induction treatment with TNF-alpha inhibitor and methotrexate in early psoriatic arthritis: an open-label extension of a randomized placebo-controlled trial. de Jong HMY; van Mens LJJ; Nurmohamed MT; Kok MR; van Kuijk AWR; Baeten DLP; van de Sande MGH Arthritis Res Ther; 2019 Sep; 21(1):208. PubMed ID: 31521192 [TBL] [Abstract][Full Text] [Related]
7. Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial. van Mulligen E; Weel AE; Hazes JM; van der Helm-van Mil A; de Jong PHP Ann Rheum Dis; 2020 Sep; 79(9):1174-1181. PubMed ID: 32482645 [TBL] [Abstract][Full Text] [Related]
8. Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy. Chang CY; Meyer RM; Reiff AO Arthritis Care Res (Hoboken); 2015 May; 67(5):658-66. PubMed ID: 25220674 [TBL] [Abstract][Full Text] [Related]
9. The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors. Martínez-Feito A; Plasencia-Rodríguez C; Navarro-Compán V; Hernández-Breijo B; González MÁ; Monjo I; Nuño L; Nozal P; Pascual-Salcedo D; Balsa A Clin Rheumatol; 2019 Mar; 38(3):949-954. PubMed ID: 30402698 [TBL] [Abstract][Full Text] [Related]
10. PERFECTRA: a pragmatic, multicentre, real-life study comparing treat-to-target strategies with baricitinib versus TNF inhibitors in patients with active rheumatoid arthritis after failure on csDMARDs. van de Laar CJ; Oude Voshaar MAH; Ten Klooster P; Tedjo DI; Bos R; Jansen T; Willemze A; Versteeg GA; Goekoop-Ruiterman YPM; Kroot EJ; van de Laar M RMD Open; 2024 May; 10(2):. PubMed ID: 38816210 [TBL] [Abstract][Full Text] [Related]
11. Risk factors for flare and treatment of disease flares during pregnancy in rheumatoid arthritis and axial spondyloarthritis patients. van den Brandt S; Zbinden A; Baeten D; Villiger PM; Østensen M; Förger F Arthritis Res Ther; 2017 Mar; 19(1):64. PubMed ID: 28320445 [TBL] [Abstract][Full Text] [Related]
12. Two-year Outcomes of Infliximab Discontinuation in Patients with Rheumatoid Arthritis: A Retrospective Analysis from a Single Center. Takai C; Ito S; Kobayashi D; Nemoto T; Lee H; Abe A; Otani H; Nakazono K; Murasawa A; Ishikawa H Intern Med; 2020; 59(16):1963-1970. PubMed ID: 32801270 [TBL] [Abstract][Full Text] [Related]
13. Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: first-year results of the randomised controlled TARA study. van Mulligen E; de Jong PHP; Kuijper TM; van der Ven M; Appels C; Bijkerk C; Harbers JB; de Man Y; Molenaar THE; Tchetverikov I; Goekoop-Ruiterman YPM; van Zeben J; Hazes JMW; Weel AEAM; Luime JJ Ann Rheum Dis; 2019 Jun; 78(6):746-753. PubMed ID: 30954969 [TBL] [Abstract][Full Text] [Related]
14. Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial. Lillegraven S; Paulshus Sundlisæter N; Aga AB; Sexton J; Olsen IC; Lexberg ÅS; Madland TM; Fremstad H; Høili CA; Bakland G; Spada C; Haukeland H; Hansen IM; Moholt E; Uhlig T; Solomon DH; van der Heijde D; Kvien TK; Haavardsholm EA Ann Rheum Dis; 2023 Nov; 82(11):1394-1403. PubMed ID: 37607809 [TBL] [Abstract][Full Text] [Related]
15. Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor in rheumatoid arthritis patients who discontinued a first TNF inhibitor. Santos-Faria D; Tavares-Costa J; Eusébio M; Leite Silva J; Ramos Rodrigues J; Sousa-Neves J; Duarte AC; Lopes C; Valido A; Dinis J; Freitas J; Santiago M; Ferreira R; Ganhão S; Miranda L; Peixoto D; Teixeira F; Alcino S; Afonso C; Santos MJ Acta Reumatol Port; 2019; 44(2):103-113. PubMed ID: 31243259 [TBL] [Abstract][Full Text] [Related]
16. Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register. Bechman K; Oke A; Yates M; Norton S; Dennison E; Cope AP; Galloway JB Rheumatology (Oxford); 2020 Sep; 59(9):2563-2571. PubMed ID: 31998962 [TBL] [Abstract][Full Text] [Related]
17. Long-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Naïve Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis. Gulácsi L; Zrubka Z; Brodszky V; Rencz F; Alten R; Szekanecz Z; Péntek M Adv Ther; 2019 Mar; 36(3):721-745. PubMed ID: 30637590 [TBL] [Abstract][Full Text] [Related]
18. Optimizing the expediency of TNFi in rheumatoid arthritis: offering a TNFi holiday in patients having reached low-disease activity in the maintenance phase. van Ingen IL; Lamers-Karnebeek F; Jansen TL Expert Opin Biol Ther; 2014 Dec; 14(12):1761-7. PubMed ID: 25366268 [TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of TNF inhibitor vs IL-6 receptor inhibitor as monotherapy or combination therapy with methotrexate in biologic-experienced patients with rheumatoid arthritis: An analysis from the CorEvitas RA Registry. Sebba A; Bingham CO; Bykerk VP; Fiore S; Ford K; Janak JC; Pappas DA; Blachley T; Dave SS; Kremer JM; Yu M; Choy E Clin Rheumatol; 2023 Aug; 42(8):2037-2051. PubMed ID: 37060528 [TBL] [Abstract][Full Text] [Related]
20. Limited value for ultrasonography in predicting flare in rheumatoid arthritis patients with low disease activity stopping TNF inhibitors. Lamers-Karnebeek FB; Luime JJ; Ten Cate DF; Teerenstra S; Swen NWAA; Gerards AH; Hendrikx J; van Rooyen EM; Voorneman R; Haagsma C; Basoski N; de Jager M; Ghiti Moghadam M; Efde MN; Goekoop-Ruiterman YPM; van Riel PLCM; Jacobs JWG; Jansen TL Rheumatology (Oxford); 2017 Sep; 56(9):1560-1565. PubMed ID: 28595367 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]